Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology.

Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE

Original Publication: Athens, Greece : D. A. Spandidos

Drugs, Chinese Herbal/*chemistry ; Drugs, Chinese Herbal/*pharmacology ; Pharmacology/*methods; Algorithms ; Computational Biology/methods ; Databases, Pharmaceutical ; Drug Compounding ; Drug Discovery/methods ; Drug Evaluation, Preclinical/methods ; Gene Expression Regulation/drug effects ; Humans ; Phytochemicals/chemistry ; Phytochemicals/pharmacology ; Signal Transduction/drug effects

Yinchenhao decoction (YCHD) is a traditional Chinese medicine formulation, which has been widely used for the treatment of jaundice for 2,000 years. Currently, YCHD is used to treat various liver disorders and metabolic diseases, however its chemical/pharmacologic profiles remain to be elucidated. The present study identified the active compounds and significant pathways of YCHD based on network pharmacology. All of the chemical ingredients of YCHD were retrieved from the Traditional Chinese Medicine Systems Pharmacology database. Absorption, distribution, metabolism and excretion screening with oral bioavailability (OB) screening, drug‑likeness (DL) and intestinal epithelial permeability (Caco‑2) evaluation were applied to discover the bioactive compounds in YCHD. Following this, target prediction, pathway identification and network construction were employed to clarify the mechanism of action of YCHD. Following OB screening, and evaluation of DL and Caco‑2, 34 compounds in YCHD were identified as potential active ingredients, of which 30 compounds were associated with 217 protein targets. A total of 31 significant pathways were obtained by performing enrichment analyses of 217 proteins using the JEPETTO 3.x plugin, and 16 classes of gene‑associated diseases were revealed by performing enrichment analyses using Database for Annotation, Visualization and Integrated Discovery v6.7. The present study identified potential active compounds and significant pathways in YCHD. In addition, the mechanism of action of YCHD in the treatment of various diseases through multiple pathways was clarified.

Bioinformatics. 2014 Apr 1;30(7):1029-30. (PMID: 24363376)
J Ethnopharmacol. 2015 Sep 15;173:91-9. (PMID: 26192807)
PLoS One. 2016 May 13;11(5):e0155264. (PMID: 27175782)
BMC Complement Altern Med. 2008 Oct 14;8:58. (PMID: 18854039)
Zhong Yao Cai. 2011 Oct;34(10):1648-51. (PMID: 22372157)
Zhong Xi Yi Jie He Xue Bao. 2011 Apr;9(4):423-34. (PMID: 21486556)
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90. (PMID: 17502601)
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13. (PMID: 14967450)
Nat Biotechnol. 2007 Oct;25(10):1110-1. (PMID: 17921993)
Asian Pac J Cancer Prev. 2015 ;16(7):3035-42. (PMID: 25854402)
Zhong Yao Cai. 2001 Feb;24(2):128-31. (PMID: 11402731)
J Ethnopharmacol. 2013 Jan 9;145(1):1-10. (PMID: 23142198)
Zhongguo Zhong Yao Za Zhi. 2015 Sep;40(17):3435-43. (PMID: 26978986)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Brief Bioinform. 2014 Sep;15(5):710-33. (PMID: 23736100)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Curr Pharm Biotechnol. 2012 Jan;13(1):173-9. (PMID: 21466430)
Biomol Ther (Seoul). 2016 Jul 1;24(4):395-401. (PMID: 27350340)
J Ethnopharmacol. 2014 Mar 28;152(3):478-86. (PMID: 24495472)
World J Gastroenterol. 2015 Jul 21;21(27):8352-7. (PMID: 26217086)
Bioinformatics. 2010 Jun 15;26(12):i246-54. (PMID: 20529913)
Evid Based Complement Alternat Med. 2013;2013:257909. (PMID: 24191164)
Curr Top Med Chem. 2012;12(12):1356-62. (PMID: 22690682)
Int Immunopharmacol. 2015 Dec;29(2):701-707. (PMID: 26388189)
PLoS One. 2012;7(9):e46318. (PMID: 23029478)
Drug Des Devel Ther. 2015 May 28;9:2793-800. (PMID: 26060396)
J Tradit Chin Med. 2011 Sep;31(3):220-3. (PMID: 21977865)
Phytother Res. 2002 Aug;16(5):417-21. (PMID: 12203259)
Int Rev Immunol. 2013 Aug;32(4):397-427. (PMID: 23886342)
Cell Biol Int. 2016 Feb;40(2):196-203. (PMID: 26493029)
J Ethnopharmacol. 2015 Jun 20;168:208-16. (PMID: 25849734)
Pharmacol Rev. 2004 Dec;56(4):549-80. (PMID: 15602010)
J Cheminform. 2014 Apr 16;6:13. (PMID: 24735618)
Nat Commun. 2014 Jun 26;5:4212. (PMID: 24967666)
Nutr Cancer. 2015;67(8):1214-20. (PMID: 26473555)
Sci Signal. 2010 Apr 20;3(118):ra30. (PMID: 20407125)
Anticancer Agents Med Chem. 2015 Sep 30;:null. (PMID: 26419468)
Tumour Biol. 2016 Oct;37(10 ):12927-12939. (PMID: 27448306)
Immunobiology. 2006;211(10):815-20. (PMID: 17113919)
Chin J Integr Med. 2009 Jun;15(3):204-9. (PMID: 19568713)
J Integr Med. 2015 Jul;13(4):262-8. (PMID: 26165371)
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Aug;30(8):845-50. (PMID: 21038655)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Endocr Relat Cancer. 2004 Dec;11(4):725-48. (PMID: 15613448)
Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):485-94. (PMID: 26253076)
Pharmacogn Rev. 2016 Jul-Dec;10 (20):84-89. (PMID: 28082789)
Semin Cancer Biol. 2016 Aug;39:15-25. (PMID: 27402288)
Int J Mol Sci. 2012;13(6):6964-82. (PMID: 22837674)
Zhongguo Zhong Yao Za Zhi. 2014 Apr;39(8):1473-8. (PMID: 25039185)
Zhongguo Zhong Yao Za Zhi. 2012 May;37(9):1327-31. (PMID: 22803386)
Yao Xue Xue Bao. 2010 Dec;45(12):1472-7. (PMID: 21351485)
J Pediatr Surg. 2011 May;46(5):994-7. (PMID: 21616268)

0 (Drugs, Chinese Herbal)
0 (Phytochemicals)
0 (yinchenhao)

Date Created: 20170810 Date Completed: 20180521 Latest Revision: 20220408

20240829

PMC5646998

10.3892/mmr.2017.7149

28791364